CN106084051A - A kind of anti-type 1 diabetes ZnT8 specific single-chain antibody scFv C27 and application thereof - Google Patents

A kind of anti-type 1 diabetes ZnT8 specific single-chain antibody scFv C27 and application thereof Download PDF

Info

Publication number
CN106084051A
CN106084051A CN201610523803.4A CN201610523803A CN106084051A CN 106084051 A CN106084051 A CN 106084051A CN 201610523803 A CN201610523803 A CN 201610523803A CN 106084051 A CN106084051 A CN 106084051A
Authority
CN
China
Prior art keywords
znt8
scfv
diabetes
type
specific single
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201610523803.4A
Other languages
Chinese (zh)
Other versions
CN106084051B (en
Inventor
张梅
张晓�
杨涛
吴倩
陈恒
秦瑶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN106084051A publication Critical patent/CN106084051A/en
Application granted granted Critical
Publication of CN106084051B publication Critical patent/CN106084051B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention discloses a kind of anti-type 1 diabetes ZnT8 specific single-chain antibody scFv C27 and application thereof.The aminoacid sequence of described anti-type 1 diabetes ZnT8 specific single-chain antibody is as shown in SEQ ID NO.5, and its coding gene sequence is as shown in SEQ ID NO.6.The present invention successfully constructs T1D scFv phage library, screens and identify ZnT8 specificity scFv, and this ZnT8 specificity scFv can be used for type 1 diabetes diagnosis, treatment and/or the preparation of Index for diagnosis reagent.

Description

A kind of anti-type 1 diabetes ZnT8 specific single-chain antibody scFv-C27 and application thereof
Technical field
The invention belongs to biomedicine technical field, relate to a kind of anti-type 1 diabetes ZnT8 specific single-chain antibody scFv- C27 and application thereof.
Background technology
Zinc transporter (ZnT) is one group of transmembrane protein being gone out outside born of the same parents by intracellular transport by zinc ion, with ZIP family protein altogether With the balance safeguarding intraor extracellular zinc ion.2004, Cheimienti etc. found ZnT8 albumen first in ZnT family, it By SLC30A8 gene code, the expression of high special in pancreas, after further study show that expression special for ZnT8 is at islets of langerhans On β cell, in INS-1 cell, process LAN ZnT8 can promote the gathering of zinc ion and strengthen sugared post-stimulatory insulin releasing. These researchs show that ZnT8 plays a significant role in the synthesis of insulin and secretion.
Type 1 diabetes (T1D) is by T cell mediated, special with the organ that selective destruction beta Cell of islet is characterized Property autoimmune disease.Multiple autoantigen is there is, such as insulin, glutamate decarboxylase (GAD), cheese on beta Cell of islet Propylhomoserin phosphatase and ZnT8.Wherein, ZnT8 is considered as an important autoantigen of T1DM, and Wenzlau etc. finds part T1D high-risk patient premorbid i.e. can detect that ZnT8 autoantibody and long term maintenance are in higher level for 2 years.We send out early-stage Study Existing ZnT8 also exist multiple epitope can by type 1 diabetes patient's autoreactive T cell identification, and ZnT8 antibody horizontal with The development of T1D also exists significant correlation.Detection ZnT8 antibody and ZnT8 specific C D8+T cell are prediction and diagnosis in early days The important means of T1D.Specific treatment for ZnT8 target spot will become the potential method stoping T1D progress.
Antibody research has more than 100 year history so far, and within 1975, Kohler and Milstein foundes B lymphocyte hybridoma Technology, Mus resource monoclonal antibody is widely used in diagnosis and the treatment of disease, but owing to human body is had by Mus resource monoclonal antibody Immunogenicity, be easily generated human antimouse antibody reaction (human anti-mouse antibody, HAMA and allergy, and due to Its molecular weight is bigger, it is difficult to wear the shortcomings such as film, limits its application in disease treatment field.From mid-1980s in 20th century Phase, along with the technical progress of molecular biology, foreign scholar establishes phage antibody library technique.Due to phage expression ScFv antibody molecule amount is less, only 1/6th of complete antibody molecule, and has preferable blood vessel or tissue barrier penetrates Property, half-life be short, Stability Analysis of Structures, without Fc section, decrease the advantages such as the adverse effect that is combined and bring with internal Fc receptor, It is widely used in molecular biology and the medical domain such as immunology, pharmacology, is current study hotspot.But have not yet to see The relevant report of anti-type 1 diabetes ZnT8 specific single-chain antibody.
Summary of the invention
It is an object of the invention to the above-mentioned deficiency for prior art, it is provided that a kind of anti-type 1 diabetes ZnT8 specificity list Chain antibody.
It is a further object of the present invention to provide the application of this single-chain antibody.
The purpose of the present invention can be achieved through the following technical solutions:
Anti-type 1 diabetes ZnT8 specific single-chain antibody scFv-C27, including heavy chain and light chain,
The aminoacid sequence of the variable region of described light chain is as shown in SEQ ID NO.1；
The aminoacid sequence of the variable region of described heavy chain is as shown in SEQ ID NO.2.
The aminoacid sequence of described anti-type 1 diabetes ZnT8 specific single-chain antibody is preferably as shown in SEQ ID NO.5.
A kind of gene encoding anti-type 1 diabetes ZnT8 specific single-chain antibody scFv-C27 of the present invention, wherein,
The gene order of the variable region of coding light chain is as shown in SEQ ID NO.3；
The gene order of the variable region of encoding heavy chain is as shown in SEQ ID NO.4.
Encode the nucleotides sequence of the gene of anti-type 1 diabetes ZnT8 specific single-chain antibody scFv-C27 of the present invention Row are preferably as shown in SEQ ID NO.6.
Anti-type 1 diabetes ZnT8 specific single-chain antibody scFv-C27 of the present invention preparation type 1 diabetes diagnosis, Application in treatment and/or Index for diagnosis reagent.
Anti-type 1 diabetes ZnT8 specific single-chain antibody scFv-described in fgs encoder claim 1 of the present invention The application in preparation type 1 diabetes diagnosis, treatment and/or Index for diagnosis reagent of the gene of C27.
Beneficial effect:
The present invention constructs a storage capacity first from patient's T1D peripheral blood gene and reaches 1 × 108ScFv phage antibody Storehouse.We have recruited the T1D patient of 50 example onsets to ensure the specificity in storehouse, multiformity and representativeness.From this storehouse, Wo Menke To screen the various autoantibodys of T1D.
ZnT8 antigen is the important autoantigen of T1D, has six transmembrane structure, and it is by SCL30A8 gene code, location On No. 8 chromosome q24.11 of people, comprise 8 exons, encode 369 aminoacid.ZnT8 autoantibody is in the generation of T1D Development has played important function.At present, amino terminal (1-74aa) and the carboxyl terminal (268-369aa) of ZnT8 albumen is recognized For being the main region of autoreactive T cell identification.Owing to ZnT8 albumen affects synthesis and the secretion of insulin, thus right Treatment T1D is significant by the deep understanding of its antibody mechanism of action.The present invention has successfully screened ZnT8 specificity scFv.For Ensureing the multiformity of the selection result, we have selected the amino carboxyl fusogenic peptide of ZnT8 albumen and carry out the screening of scFv.Have A large amount of reports find that in T1D patient, ZnT8 antigen 325 amino acids also exists point mutation, is sported cheese ammonia by arginine (Arg) Acid (Trp), this site mutation is closely related with the identification of ZnT8 antibody, the sudden change dimer of ZnT8 carboxyl terminal (Arg325Trp) detection ZnT8 antibody is had specificity and the sensitivity of height.So we use ZnT8 carboxyl further The dimer (Arg325Trp) of end identifies scFv-C27, and result shows that scFv-C27 can be combined with this dimer.Immune group Change result and show scFv energy specific recognition islet cells further, there is good biologic activity.
The present invention successfully constructs T1D scFv phage library, screens and identify ZnT8 specificity scFv, and this ZnT8 is special Opposite sex scFv can be used for type 1 diabetes diagnosis, treatment and/or the preparation of Index for diagnosis reagent.
Accompanying drawing explanation
Fig. 1. the restructuring gene constructed .M of ZnT8: nucleic acid standards；Swimming lane 1:ZnT8 amino terminal gene (1-74aa) is about 250bp；Swimming lane 2:ZnT8 carboxyl terminal gene (268-369aa) about 350bp；Swimming lane 3:ZnT8 amino carboxyl fusion gene (1- 74aa, 268-369aa) about 550bp；Swimming lane 4:ZnT8 c-terminus dimerization mutant gene (Arg325Trp) about 650bp.Fig. 2. The expression and purification of restructuring ZnT8 albumen and qualification.
The Western blotting of A:ZnT8 amino carboxyl fusion protein detects (swimming lane 1: before protein purification；Swimming lane 2: Albumen after purification；Swimming lane 3: flow through)；The SDS-PAGE of B:ZnT8 amino carboxyl fusion protein detects (M: protein standard substance；Swimming Road 1: before protein purification；Swimming lane 2: albumen after purification；Swimming lane 3: flow through)；C:ZnT8 c-terminus dimerization mutant protein Western blotting detects (swimming lane 1: before protein purification；Swimming lane 2: albumen after purification；Swimming lane 3: flow through)；D:ZnT8 carboxylic Cardinal extremity dimerization mutant protein SDS-PAGE detects (M: protein standard substance；Swimming lane 1: before protein purification；Swimming lane 2: egg after purification In vain；Swimming lane 3: flow through).
ZnT8 amino carboxyl fusion protein and c-terminus dimerization mutant protein molecular weight the most about 20kD and 25kD.
Fig. 3 .ELISA detection amino carboxyl fusion protein and the binding ability of commercialization ZnT8 antibody.
Fig. 4 .T1D scFv gene amplification .M: nucleic acid standards；Swimming lane 1:V λ PCR primer (～350bp)；Swimming lane 2:V κ PCR primer (～350bp)；Swimming lane 3:VH PCR primer (～450bp)；Swimming lane 4:scFv PCR primer (～800bp).
The purification of Fig. 5 .scFv-C27 and qualification.
A.SDS-PAGE detects scFv (M: protein standard substance；Swimming lane 1:scFv-C27 is before purification；Swimming lane 2: after purification scFv-C27；Swimming lane 3:scFv-C27 flows through)；B.Western blotting analyze detects scFv (swimming lane 1:scFv- C27 is before purification；Swimming lane 2: scFv-C27 after purification；Swimming lane 3:scFv-C27 flows through).
The binding ability of Fig. 6 .Western blotting detection scFv Yu ZnT8 amino carboxyl fusion protein.
Swimming lane 1:scFv-C27 detects ZnT8 amino carboxyl fusion protein；Swimming lane 2: negative control.
Fig. 7 .scFv-C27 detects with the affinity of ZnT8 amino carboxyl fusion protein.
Fig. 8 .ELISA detects the scFv-C27 binding ability to ZnT8 c-terminus dimerization mutant protein.
Fig. 9. identification ability (A: the islet cells HE coloration result of SABC detection scFv antibody on human pancreatic tissue； B:C27 detects islet cells result.Row 1: amplify 40 times；Row 2: amplify 200 times)
Detailed description of the invention
Embodiment 1 is recombinated the construction and expression of ZnT8 prokaryotic expression plasmid
Design primer ZF and LR (table 1), with ZnT8 plasmid (purchased from Sino Biological Inc., HG11621-M) being template, expand people's ZnT8 amino terminal (1-74aa) gene, design primer LF and CR (table 1), with ZnT8 matter Grain is template, expands people's ZnT8 carboxyl terminal (269-368aa) gene, PCR primer glue passes through with primer ZF and CR after reclaiming Overlap builds amino carboxyl fusion gene.
ZnT8 carboxyl terminal dimerization mutant base is designed with reference to the SEQ ID No.55 in US9023984 (B2) sequence table Cause, as shown in SEQ ID No.7, and entrusts biotech firm to synthesize, this dimer contain 2 people's ZnT8 carboxyl terminal genes, first Individual is arginine (Arg) 325 for aminoacid, and second is tyrosine (Trp) at 325,2 people's ZnT8 carboxylics in this dimer Base terminal gene passes through one section of flexible peptide linkage.Design primer CF and CR is used for expanding ZnT8 c-terminus dimerization mutant gene.
Table 1. primer sequence
Primer ZF and LR is used for expanding ZnT8 amino terminal gene (1-74aa), and primer LF and CR is used for expanding ZnT8 carboxyl Terminal gene (268-369aa), primer ZF and CR expands ZnT8 amino carboxyl fusion gene, primer CF and CR for overlap For expanding ZnT8 c-terminus dimerization mutant gene.
Above-mentioned two recombination inserts in pcold II plasmid respectively after SacI and XbaI double digestion.Connect product to turn Select positive colony after dissolving e. coli bl21 (DE3) cultivation to check order.By correct being cloned in LB culture medium of checking order 37 DEG C are expanded to after D (600) value reaches 1.0 add IPTG derivant extremely final concentration of 1mM/L, 15 DEG C of abduction delivering 24h.4 DEG C, 10 -80 DEG C of preservations of 000 × g collected after centrifugation thalline.
People's ZnT8 amino carboxyl fusion protein of purification is coated elisa plate, from 1.6ug/ hole doubling dilution to 0.1ug/ Hole, detection fusion albumen changes with the dose-effect of the ZnT8 antibodies of commercialization.
ZnT8 amino carboxyl fusion gene about 550bp, carboxyl dimerization mutant gene about 650bp, PCR primer electrophoresis result Seeing Fig. 1, be all successively inserted into pcold II carrier, sequencing result is consistent with theory.
Antigen is shown in Fig. 2 through expression and purification renaturation rear electrophoresis result, it is seen that ZnT8 amino carboxyl fusogenic peptide molecular weight after purification About 20kD, carboxyl dimerization mutant molecule amount about 25kD.
ELISA detection display ZnT8 amino carboxyl fusion protein can be combined with the ZnT8 antibody specificity of commercialization, available Screening (Fig. 3) in ZnT8 specificity scFv.
The structure of embodiment 2T1D scFv phage antibody library
Experimental specimen is the peripheral blood of the T1D volunteer of 50 onsets.Wherein 31 volunteers sera's ZnT8 antibody positives. Serum Zn T8 antibody horizontal by radioimmunity part method carry out detecting (method detailed sees Gu Y, Zhang M, Chen H, Wang Z,Xing C,Yang H,et al.Discordant association of islet autoantibodies with high-risk hla genes in chinese type 1diabetes.Diabetes/metabolism research and reviews 2011；27:899-905).All patients all sign Informed Consent Form.Sorting T1D volunteer Peripheral blood PBMC.Extracting T1D volunteer peripheral blood PBMC RNA, then reverse transcription synthesis cDNA, concrete operation step is illustratively Book is carried out.By RT-PCR method, with human single chain variable fragments antibody (scFv) universal primer (table 2) amplification heavy chain and light chain, pass through Overlap PCR is linked into scFv, inserts pcomb3XSS plasmid (purchased from BioVector NTCC preservation after Sfi I enzyme action The heart) in.Connect product and be transformed into escherichia coli XL1-Blue (purchased from Stratagene, Cat.#200228) through repeatedly electricity, use Helper phage VCSM13 superinfection is added after SB culture medium amplification culture.Collect supernatant next day after PEG-8000/NaCl precipitates Obtain T1D scFv phage antibody library.
Table 2. people source scFv universal primer sequence
Note: R=A or G Y=C or C M=A or C K=G or T S=C or G W=A or T H=A Or C or T B=C or G or T V=A or C or G D=A or G or T N=A or C or G or T
Amplification VH strand primer combination is as follows:
Amplification VκPrimer combination is as follows:
Amplification VλPrimer combination is as follows:
Above-mentioned Successful amplification heavy chain of antibody and light chain after RT-PCR, size about 400bp, single-chain antibody gene band exists About 750bp (Fig. 4), glue inserts in pcomb3XSS carrier after reclaiming, and electricity is transformed into escherichia coli XL1-Blue, through VCSM13 Obtaining phage antibody library after superinfection, storage capacity is 1 × 10 after testing8。
1.2.4ZnT8 the screening of specificity scFv
The ZnT8 amino carboxyl fusion protein of purification is coated elisa plate by 1 μ g/ hole, through 4 take turns " absorption ", " wash De-", " amplification " (Zhang X, Qi X, Zhang Q, Zeng X, Shi Z, Jin Q, et al.Human 4f5single-afterwards chain fv antibody recognizing a conserved ha1epitope has broad neutralizing potency against h5n1influenza a viruses of different clades.Antiviral research 2013；99:91-9), phage-ELISA detects.Select the high positive colony of OD value extract plasmid and send survey Sequence, sequencing result and human immunoglobulin sequence (IMGT data base) (Ehrenmann F, Kaas Q, Lefranc MP.Imgt/3dstructure-db and imgt/domaingapalign:A database and a tool for immunoglobulins or antibodies,T cell receptors,mhc,igsf and mhcsf.Nucleic acids research 2010；38:D301-7.Lefranc MP,Giudicelli V,Duroux P,Jabado- Michaloud J,Folch G,Aouinti S,et al.Imgt(r),the international immunogenetics information system(r)25years on.Nucleic acids research 2015；43:D413-22.) carry out Comparison also carries out the division of CDR region.
Through 4 screenings taken turns, ZnT8 specificity scFv is enriched with.Each phage titre of taking turns is shown in Table 3.Last is taken turns After the phage-infect escherichia coli XL1-Blue of eluting, randomly choose 160 clones.Phage ELISA result shows 23 Individual positive colony, wherein has 11 clone's OD values higher, obtains 7 strain scFv through order-checking.We have carried out CDR to this 7 strain scFv The division in district, all meets people source scFv antibody characteristic.Wherein, scFv-C27 and C22OD value is the highest, and therefore we select scFv- C27 makes further research.
The enrichment of table 3.ZnT8 specific bacteriophage antibody
The phage density (pfu) before phage density (pfu) × 100/ absorption after yield (%)=eluting
By checking order, correct positive colony is transformed into escherichia coli Top10F ', chooses monoclonal colony inoculation in containing 20mM In the SB culture medium of MgCl2, after 37 DEG C of shaking 8h, add IPTG to final concentration 1mM, 37 DEG C of abduction delivering 24h.4 DEG C, 10 000* -80 DEG C of preservations of g collected after centrifugation thalline.
Bacterial precipitation is resuspended with the phosphate buffer containing 8M carbamide, is placed on ice, splits with sonicated cells instrument Solve.4 DEG C of centrifugal 30min of 10000*g, supernatant uses HisTrap affinity column purifying protein after 0.22 μm membrane filtration.Wash The destination protein taken off less than 0.125mM, obtains high concentration albumen by Concentraton gradient dialysis renaturation to carbamide after ultrafiltration concentration. Western Yu SDS-PAGE result shows our successful expression purification scFv-C27, its molecular weight about 30kD (Fig. 5)
The specificity analysis of embodiment 3ZnT8 specificity scFv
Western blot detects: by the restructuring ZnT8 amino carboxyl fusion protein of purification after 12% protein adhesive electrophoresis Going on pvdf membrane, after 5% milk is closed, resist as one with the scFv of purification, the HA antibody of HRP labelling resists as two, detection The combination activity of scFv-C27 Yu ZnT8.Result display scFv-C27 can detect that amino carboxyl fusion protein, at about 20kD Visible obvious band, is consistent with expection, and negative control has no band, illustrates that scFv-C27 Yu ZnT8 albumen has good knot Conjunction ability (Fig. 6).
Affinity detects: is opened up Bioisystech Co., Ltd by Suzhou hundred and completes.Affinity result display scFv-C27 with ZnT8 amino carboxyl fusion protein has higher affinity, and affinity is 5.397 × 10-8KD (M) (Fig. 7).
ELISA detects: by 0.5 μ g/ hole, the ZnT8 carboxyl terminal dimerization mutant protein of purification is coated elisa plate, ScFv-C27 is from 1:10 doubling dilution to 1:20480, the dose-effect change that detection scFv-C27 with ZnT8 is combined.As shown in Figure 8, with The doubling dilution of scFv-C27 concentration, it is gradually lowered with the binding ability of ZnT8 c-terminus dimerization mutant protein, explanation ScFv-C27 is combined with ZnT8 antigenic peptides with concentrationdependent manner.
SABC: C27 antibody is resisted by we as one, carries out immunohistochemical experiment by the method for indirect labelling, anti- Body hatch after Human Pancreas section islet cells be strong positive, illustrate that C27 antibody has good biological activity, it is possible to Special identifies the ZnT8 albumen that people's beta Cell of islet is expressed.
Result above all shows that scFv-C27 can be specific binding with people ZnT8.

Claims (6)

  1. The most anti-type 1 diabetes ZnT8 specific single-chain antibody scFv-C27, including light chain and heavy chain, it is characterised in that:
    The aminoacid sequence of the variable region of described light chain is as shown in SEQ ID NO.1；
    The aminoacid sequence of the variable region of described heavy chain is as shown in SEQ ID NO.2.
  2. Anti-type 1 diabetes ZnT8 specific single-chain antibody scFv-C27 the most according to claim 1, it is characterised in that described The aminoacid sequence of anti-type 1 diabetes ZnT8 specific single-chain antibody as shown in SEQ ID NO.5.
  3. 3. encoding a gene of anti-type 1 diabetes ZnT8 specific single-chain antibody scFv-C27 described in claim 1, it is special Levy and be:
    The nucleotide sequence of the variable region of coding light chain is as shown in SEQ ID NO.3；
    The nucleotide sequence of the variable region of encoding heavy chain is as shown in SEQ ID NO.4.
  4. Gene the most according to claim 3, it is characterised in that its nucleotide sequence is as shown in SEQ ID NO.6.
  5. 5. the anti-type 1 diabetes ZnT8 specific single-chain antibody scFv-C27 described in claim 1 or 2 is in preparation type 1 diabetes Application in diagnosis, treatment and/or Index for diagnosis reagent.
  6. 6. the anti-type 1 diabetes ZnT8 specific single-chain antibody scFv-described in the coding claim 1 described in claim 3 or 4 The application in preparation type 1 diabetes diagnosis, treatment and/or Index for diagnosis reagent of the gene of C27.
CN201610523803.4A 2016-02-17 2016-07-04 A kind of ZnT8 specific single-chain antibodies scFv C27 and its application Active CN106084051B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610089777 2016-02-17
CN2016100897779 2016-02-17

Publications (2)

Publication Number Publication Date
CN106084051A true CN106084051A (en) 2016-11-09
CN106084051B CN106084051B (en) 2018-03-02

Family

ID=57213266

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610523803.4A Active CN106084051B (en) 2016-02-17 2016-07-04 A kind of ZnT8 specific single-chain antibodies scFv C27 and its application

Country Status (1)

Country Link
CN (1) CN106084051B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106771233A (en) * 2016-12-05 2017-05-31 上海良润生物医药科技有限公司 ZnT8A autoantibody detection kits
WO2020037174A1 (en) 2018-08-16 2020-02-20 The Johns Hopkins University Antibodies to human znt8
CN114184793A (en) * 2021-12-09 2022-03-15 深圳市亚辉龙生物科技股份有限公司 Zinc transport protein 8 antibody chemiluminescence immunoassay kit and preparation method thereof
US11841363B2 (en) 2016-04-25 2023-12-12 The Johns Hopkins University ZnT8 assays for drug development and pharmaceutical compositions
US11892457B2 (en) 2017-07-12 2024-02-06 The Johns Hopkins University Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101646781A (en) * 2006-12-29 2010-02-10 科罗拉多大学董事会 The diagnosis of autoimmune disease and treatment target and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101646781A (en) * 2006-12-29 2010-02-10 科罗拉多大学董事会 The diagnosis of autoimmune disease and treatment target and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘宝英: "锌转运体8多克隆抗体的制备及功能初步研究", 《中国博士学位论文全文数据库（医药卫生科技辑）》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11841363B2 (en) 2016-04-25 2023-12-12 The Johns Hopkins University ZnT8 assays for drug development and pharmaceutical compositions
CN106771233A (en) * 2016-12-05 2017-05-31 上海良润生物医药科技有限公司 ZnT8A autoantibody detection kits
US11892457B2 (en) 2017-07-12 2024-02-06 The Johns Hopkins University Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
WO2020037174A1 (en) 2018-08-16 2020-02-20 The Johns Hopkins University Antibodies to human znt8
CN113166241A (en) * 2018-08-16 2021-07-23 约翰霍普金斯大学 Human ZNT8 antibodies
CN114184793A (en) * 2021-12-09 2022-03-15 深圳市亚辉龙生物科技股份有限公司 Zinc transport protein 8 antibody chemiluminescence immunoassay kit and preparation method thereof
CN114184793B (en) * 2021-12-09 2023-08-11 深圳市亚辉龙生物科技股份有限公司 Zinc transport protein 8 antibody chemiluminescence immunoassay kit and preparation method thereof

Also Published As

Publication number Publication date
CN106084051B (en) 2018-03-02

Similar Documents

Publication Publication Date Title
CN109265548B (en) anti-PD-L1 nano antibody and coding sequence, preparation method and application thereof
CN106084051A (en) A kind of anti-type 1 diabetes ZnT8 specific single-chain antibody scFv C27 and application thereof
TWI779479B (en) Antigen binding molecules and methods of use thereof
CN106519019B (en) Identify the TCR of PRAME antigen
CN106749620B (en) T cell receptor for recognizing MAGE-A1 antigen short peptide
CN104395342B (en) The antibody in the anti-fibronectin ED B structures domain in people source and application thereof
AU2015209171B2 (en) Antibodies against F glycoprotein of Hendra and Nipah viruses
CN104955841A (en) Method and kit for detecting 1,25-dihydroxyvitamin D and related antibodies
CN102659945B (en) Anti-C5aR antibody and application thereof
CN106478808B (en) Identify the T cell receptor of NY-ESO-1 antigen small peptides
CN108699729A (en) The libraries TCR
CN106831978A (en) Recognize the φt cell receptor of DAGE
CN110343166A (en) Identify the T cell receptor of AFP antigen small peptide
CN106084043B (en) A kind of ZnT8 specific single-chain antibodies scFv C22 and its application
JP6707660B2 (en) Anti-podocalyxin-like protein precursor subtype 2 monoclonal antibody, production method and use thereof
TW201811828A (en) Antigen binding molecules and methods of use thereof
CN106699874A (en) T cell receptor identifying PRAME antigenic short-peptide
CN106336457B (en) Identify the φt cell receptor of MAGE A3 antigen small peptides
Moreland et al. Phage display approaches for the isolation of monoclonal antibodies against dengue virus envelope domain III from human and mouse derived libraries
CN110655581B (en) Anti-carcinoembryonic antigen antibody and preparation method and application thereof
CN111349161A (en) Monoclonal antibody of anti-CD 19 antibody and application thereof
CN106459179B (en) Identify the T cell receptor of RHAMM antigen small peptides
CN109575121A (en) Identify the T cell receptor of AFP antigen small peptide
CN106188298B (en) A kind of Vsig4 nano antibody and its epitope identification method and application
CN109251244A (en) A kind of identification is derived from the TCR of EBV memebrane protein LMP1 antigen

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant